In the original article, there was a mistake in Figures 2 and 5 as published. The presented figure of siPAR1 (0 h) in Figure 2A and the presented figure of Group 30 μM (cells treated with 30 μM of doxycycline) in Figure 5E were wrongly presented in the original article. Furthermore, the annotation in the ordinate axis of the statistical figure in Figures 2B and 5E should be “invasion cells per field” not the “passed cells per field.” The corrected Figures 2 and 5 appear below.
Figure 2
Figure 5
The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.
Publisher’s Note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
Summary
Keywords
protease activation receptor 1, focal adhesion kinase, doxycycline, epithelial–mesenchymal transformation, pancreatic cancer stem cells
Citation
Liu H, Tao H, Wang H, Yang Y, Yang R, Dai X, Ding X, Wu H, Chen S and Sun T (2022) Corrigendum: Doxycycline Inhibits Cancer Stem Cell-Like Properties via PAR1/FAK/PI3K/AKT Pathway in Pancreatic Cancer. Front. Oncol. 12:830506. doi: 10.3389/fonc.2022.830506
Received
07 December 2021
Accepted
24 January 2022
Published
24 February 2022
Volume
12 - 2022
Edited and reviewed by
Zhi-xiang Yuan, Southwest Minzu University, China
Updates
Copyright
© 2022 Liu, Tao, Wang, Yang, Yang, Dai, Ding, Wu, Chen and Sun.
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Tao Sun, tao.sun@nankai.edu.cn; Huijuan Liu, liuhuijuanxyz@163.com
†These authors have contributed equally to this work
This article was submitted to Pharmacology of Anti-Cancer Drugs, a section of the journal Frontiers in Oncology
Disclaimer
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.